Gold prices edge higher; Fed indepedence fears spur safe haven buying
In a recent transaction reported to the SEC, Luke Evnin, a director and significant shareholder of Werewolf Therapeutics , Inc. (NASDAQ:HOWL), sold 2,425 shares of the company’s common stock. This sale, conducted on March 27, 2025, was executed at a price of $1.05 per share, amounting to a total value of $2,546. The transaction price represents a premium to the current trading price of $0.90, with the stock having declined over 86% in the past year. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value assessment.
The transaction was part of a broader set of activities involving the exercise of warrants. Evnin exercised warrants to acquire 28,113 shares of common stock at a price of $0.09 per share, resulting in a cashless exercise where 2,425 shares were withheld to cover the exercise costs. Consequently, 25,688 shares were issued to Evnin. With a market capitalization of just $40.3 million, analysts maintain a strong buy consensus with price targets ranging from $4 to $15.
Following these transactions, Evnin’s indirect holdings, managed through various investment vehicles, totaled 4,309,860 shares. These shares are held through entities such as MPM (BVMF:ESPA3) Asset Management LLC and MPM BioVentures, among others. Evnin’s role in these entities includes positions as a member and managing director, though he disclaims beneficial ownership beyond his financial interest. InvestingPro data shows the company maintains a strong liquidity position with more cash than debt on its balance sheet. Get access to 10+ additional ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Werewolf Therapeutics Inc. has maintained its Market Outperform rating with a consistent price target of $4.00, according to analysts at JMP. The company is making strides in its clinical programs by selecting a recommended dose for WTX-124, which will be used in trials for melanoma, renal cell carcinoma, and cutaneous squamous cell carcinoma. An interim data update from these trials is anticipated in the fourth quarter of 2025, which could provide valuable insights into the drug’s efficacy and safety. Werewolf Therapeutics also plans to engage with the FDA in late 2025 to explore potential accelerated approval pathways for WTX-124.
In addition, Werewolf Therapeutics has announced a change to its board of directors. Dr. Derek DiRocco will resign, and Dr. Anil Singhal has been appointed as a new board member. Dr. Singhal brings over three decades of industry experience and will serve on the company’s Audit Committee. His compensation includes an annual cash fee and stock options, contingent upon his continued service. These developments highlight Werewolf Therapeutics’ ongoing efforts in advancing its clinical programs and strengthening its leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.